Navigation Links
GranuFlo Lawsuits Move Forward, as Bernstein Liebhard Notes Issuance of New Order in Federal GranuFlo Recall Litigation

New York, New York (PRWEB) July 23, 2013

GranuFlo lawsuit claims filed in the wake of the recent recall of GranuFlo and NaturaLyte dialysis concentrates are moving forward in a federal multidistrict litigation now underway in U.S. District Court, District of Massachusetts, Bernstein Liebhard LLP reports. According to court documents, the judge overseeing the GranuFlo recall litigation issued an Order on July 16th that established the proceeding’s plaintiffs' executive and steering committees. (In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428)

“We are pleased to see the GranuFlo recall litigation moving forward, as we continue to hear from dialysis patients who suffered heart attacks, stroke, cardiac arrest, and other catastrophic heart side effects, allegedly due to GranuFlo or NaturaLyte,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm continues to offer free GranuFlo lawsuit evaluations to dialysis patients who may have been harmed by these drugs.

GranuFlo and NaturaLyte Recall
Marketed by Fresenius Medical Care, GranuFlo and NaturaLyte are used during dialysis to reduce the amount of acid in the blood. In March 2012, Fresenius issued an “Urgent Product Notification” to its customer clinics warning of possible heart risks associated with the products, which would later be deemed a Class I GranuFlo recall by the U.S. Food & Drug Administration (FDA). Class I recalls are the agency’s most serious type, and are issued when a medical product poses a significant risk of serious injury or death.*

More than 300 dialysis lawsuit claims involving GranuFlo and NaturaLyte are now pending in the District of Massachusetts. According to court documents, plaintiffs allege Fresenius knew or should have known of the propensity of GranuFlo and NaturaLyte to cause injury. They further allege the Company failed to provide adequate instructions and warnings for their use.

According to a report from The New York Times, Fresenius Medical Care treats more than a third of the estimated 400,000 Americans receiving dialysis and is the leading supplier of dialysis machines and disposable products. GranuFlo and NaturaLyte were widely used at Fresenius’s own dialysis clinics, and were also used to treat an estimated 125,000 patients at clinics outside of the Fresenius network. Last summer, the FDA launched an investigation into the company’s handling of the GranuFlo recall, after learning that Fresenius had issued a memo in November 2011 to its own clinics that warned of the heart risks associated with GranuFlo and NaturaLyte, and advised doctors to adjust their dosage to avoid these dangers.**

Patients who suffered heart attacks, sudden cardiac death, and other catastrophic heart side effects within 48 hours of a dialysis treatment with GranuFlo and NaturaLyte may be entitled to file a Granuflo lawsuit to obtain compensation for medical expenses, lost wages, pain and suffering, and more. Learn more about the GranuFlo recall by visiting Bernstein Liebhard LLP’s website. For additional information, contact a lawyer at Bernstein Liebhard LLP today by calling 800-511-5092.

*; FDA, March 29, 2013
**; New York Times, June 14, 2012

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. GranuFlo Lawsuit Consolidation Supported by Fresenius Medical Care, Bernstein Liebhard LLP Reports
2. GranuFlo Recall Website Launched By Hissey Kientz, LLP Law Firm
3. d'Oliveira & Associates Releases Fresenius Infographic about the FDA Recall of NaturaLyte and GranuFlo
4. GranuFlo Lawsuits Filed in Wake of GranuFlo and NaturaLyte Recall Mount in State and Federal Courts, Bernstein Liebhard LLP Reports
5. The National Plaintiff’s Law Firm of Baron and Budd Handling Granuflo Recall Lawsuits
6. New Granuflo Cardiac Arrest Lawsuit: Now, AttorneyOne Can Provide Advice
7. GranuFlo Lawsuit News: Bernstein Liebhard LLP Reports on Growing Litigation Surrounding GranuFlo Recall
8. Fresenius, Maker of Recalled Dialysis Drugs GranuFlo And NaturaLyte, Is Back In The News With Problems At Its Dialysis Center In Bessemer, Alabama
9. GranuFlo Lawsuits Moving Forward in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports
10. Issues Report on Prostate Health Claim Lawsuits and Propecia Side Effect Litigation
11. DrugRisk Center Announces Court Postponement of NuvaRing Lawsuits
Post Your Comments:
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... a safe and convenient way to dispense prescription medications at home, so he ... effective way to monitor and dispense prescription medications. In doing so, it could ...
(Date:11/27/2015)... ... , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of ... than 3.7 billion people under the age of 50 – or 67% of the population ... global estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... an innovative online platform for mental health and wellness consultation, has collaborated with ... partnership will bridge the knowledge gap experienced by parents and bring advice from ...
(Date:11/27/2015)... ... 27, 2015 , ... Indosoft Inc., developer and distributor of ... 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. , Making ... with a version of Asterisk that will receive not only security fixes, but ...
(Date:11/26/2015)... ... ... The Catalent Applied Drug Delivery Institute today announced a ... selection in early phase drug development. The first of these is to be ... UK’s emerging life sciences companies, corporate partners, and investors, at Milton Park, Oxford, ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... STOCKHOLM , November 26, 2015 ... the potential to use SyMRI to find optimal contrast weighting ... brain tumor metastases, and has signed a research agreement with ... at the hospital. Using SyMRI, it is possible to generate ... parameter settings after the patient has left, thus making it ...
(Date:11/26/2015)... 2015 ) ... "2016 Future Horizons and Growth Strategies in ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> ) has announced ... Horizons and Growth Strategies in the French ...
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 Research ... of the "Advanced Wound Care Market by Type ... Ulcers), End User (In-Patient Facility, Out-Patient Facility), and Geography ... offering. --> --> ... the description, definition and forecast of the global advanced ...
Breaking Medicine Technology: